Boston Scientific enters into $2 billion accelerated share repurchase agreement

Boston Scientific Corporation has announced that it has entered into an accelerated share repurchase (ASR) agreement with JPMorgan Chase Bank for $2 billion of its common stock, as part of its previously announced $5 billion share repurchase authorization. Under the terms of the ASR, the company will pay the repurchase price and receive common stock valued at 80% of the repurchase price based on the closing share price of May 15, 2026, which is approximately 30.4 million shares at $52.68 per share.

The total number of shares Boston Scientific repurchases under the ASR will be determined based on the volume-weighted average price of the company's common stock during the ASR term, minus a discount and subject to certain adjustments. The final settlement of the ASR is expected to be completed by June 30, 2026, after which Boston Scientific will have $3 billion remaining under the share repurchase authorization.

The anticipated net impact to adjusted earnings per share from the accelerated share repurchase in 2026 is estimated to be $0.02, which is accretive to the company's previously issued guidance from April 22, 2026.

Boston Scientific has been a leader in medical technology for over 45 years, providing a wide range of solutions for various medical conditions and reducing healthcare costs. The company is committed to improving health outcomes for patients around the world.

The announcement contained forward-looking statements regarding the ASR's benefits, the expected impact on earnings, and the timing of share repurchases. These statements are based on current beliefs and assumptions and should not be considered guarantees of future performance, as actual outcomes could differ based on various factors, including economic conditions and competitive pressures.